Kura Oncology KURA 深 沪
等待开盘 08-10 09:30:00 美东时间
9.57
+0.290
+3.13%
华盛通- 最 高9.63
- 今 开9.37
- 成交量 73.52万股
- 最 低 9.11
- 昨 收 9.28
- 总市值 63.77万
- 52周最高 12.49
- 市盈率 静 --
- 换手率 1103.35%
- 52周最低 6.95
- 委 比 48.34%
- 总股本 6.66万
- 历史最高 43.00
- 量 比 0.58
- 振 幅 5.60%
- 历史最低 1.10
- 每 手 1
- 风险率 1.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results
Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; analysts maintain Buy ratings.
04-17 22:39
Kura Oncology Q4 EPS $(0.92) Misses $(0.59) Estimate, Sales $17.336M Miss $53.554M Estimate
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.59) by 56.2 percent. This is a 318.18 percent decrease over losses of $(0.22) per share from
03-05 19:33
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology granted stock options to five new employees under its 2023 Inducement Option Plan. The options, totaling 79,200 shares with an exercise price of $6.30, vest over four years.
2025-06-06 11:30
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
Kura Oncology and Kyowa Kirin announce FDA acceptance of the NDA for ziftomenib, a menin inhibitor, for adult patients with relapsed or refractory AML with an NPM1 mutation, with a PDUFA date of November 30, 2025.
2025-06-01 23:00
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
The ziftomenib trial for R/R NPM1-m AML has met its primary endpoint, showing encouraging efficacy and safety. Results will be presented at ASCO 2025, with an investor event planned. The companies also announced a poster presentation for another trial.
2025-05-22 21:30
Cantor Fitzgerald Reiterates Overweight on Kura Oncology
Cantor Fitzgerald analyst Li Watsek reiterates Kura Oncology (NASDAQ:KURA) with a Overweight.
2024-09-10 01:17
